Systemic Inflammation Response Index as a Predictor of Stroke Risk in Elderly Patients with Hypertension: A Cohort Study

References

• Jing M, Bao L, Seet R. Estimated incidence and mortality of stroke in China. JAMA Netw Open. 2023;6(3):e231468. doi:10.1001/jamanetworkopen.2023.1468
   PubMed Web of Science ®Google Scholar
• Ding Q, Liu S, Yao Y, Liu H, Cai T, Han L. Global, regional, and national burden of ischemic stroke, 1990–2019. Neurology. 2022;98(3):e279–e290. doi:10.1212/WNL.0000000000013115
   PubMed Web of Science ®Google Scholar
• Tian DS, Liu CC, Wang CL, et al. Prevalence and risk factors of stroke in China: a national serial cross-sectional study from 2003 to 2018. Stroke Vasc Neurol. 2023;8(3):238–248. doi:10.1136/svn-2022-001598
   PubMedGoogle Scholar
• Tu WJ, Zhao Z, Yin P, et al. Estimated burden of stroke in China in 2020. JAMA Netw Open. 2023;6(3):e231455. doi:10.1001/jamanetworkopen.2023.1455
   PubMed Web of Science ®Google Scholar
• Yao M, Ren Y, Jia Y, et al. Projected burden of stroke in China through 2050. Chin Med J. 2023;136(13):1598–1605. doi:10.1097/CM9.0000000000002060
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation. 2018;137(22):2344–2356. doi:10.1161/CIRCULATIONAHA.117.032380
   PubMed Web of Science ®Google Scholar
• Li Y, Yang L, Wang L, et al. Burden of hypertension in China: a nationally representative survey of 174,621 adults. Int J Cardiol. 2017;227:516–523. doi:10.1016/j.ijcard.2016.10.110
   PubMed Web of Science ®Google Scholar
• Liu X, Gu W, Li Z, Lei H, Li G, Huang W. Hypertension prevalence, awareness, treatment, control, and associated factors in Southwest China: an update. J Hypertens. 2017;35(3):637–644. doi:10.1097/HJH.0000000000001203
   PubMed Web of Science ®Google Scholar
• China T, Hu SS. Report on cardiovascular health and diseases in China 2021: an updated summary. J Geriatr Cardiol. 2023;20(6):399–430. doi:10.26599/1671-5411.2023.06.001
   PubMedGoogle Scholar
• Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313(13):1325–1335. doi:10.1001/jama.2015.2274
   PubMed Web of Science ®Google Scholar
• Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114. doi:10.1161/CIRCULATIONAHA.115.020406
   PubMed Web of Science ®Google Scholar
• Ganjali S, Gotto AM, Ruscica M, et al. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. J Cell Physiol. 2018;233(12):9237–9246. doi:10.1002/jcp.27028
   PubMed Web of Science ®Google Scholar
• Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11(1):117. doi:10.1186/1741-7015-11-117
   PubMed Web of Science ®Google Scholar
• Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960. doi:10.1155/2014/406960
   PubMed Web of Science ®Google Scholar
• Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474–488. doi:10.4149/BLL_2021_078
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med. 2019;39(4):345–357. doi:10.3343/alm.2019.39.4.345
   PubMed Web of Science ®Google Scholar
• Bg S, Gosavi S, Ananda Rao A, et al. Neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios: prognostic significance in COVID-19. Cureus. 2021;13(1):e12622. doi:10.7759/cureus.12622
   PubMed Web of Science ®Google Scholar
• Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50(5):e13230. doi:10.1111/eci.13230
   PubMed Web of Science ®Google Scholar
• Xiao S, Wang Z, Zuo R, et al. Association of systemic immune inflammation index with all-cause, cardiovascular disease, and cancer-related mortality in patients with cardiovascular disease: a cross-sectional study. J Inflamm Res. 2023;16:941–961. doi:10.2147/JIR.S402227
   PubMed Web of Science ®Google Scholar
• Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic Immune Inflammation Index (SII), System Inflammation Response Index (SIRI) and risk of all-cause mortality and cardiovascular mortality: a 20-year follow-up cohort study of 42,875 US adults. J Clin Med. 2023;12(3):1128. doi:10.3390/jcm12031128
   PubMed Web of Science ®Google Scholar
• Li J, He D, Yu J, et al. Dynamic status of SII and SIRI alters the risk of cardiovascular diseases: evidence from kailuan cohort study. J Inflamm Res. 2022;15:5945–5957. doi:10.2147/JIR.S378309
   PubMed Web of Science ®Google Scholar
• Huang L. Increased systemic immune-inflammation index predicts disease severity and functional outcome in acute ischemic stroke patients. Neurologist. 2023;28(1):32–38. doi:10.1097/NRL.0000000000000464
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang Y, Cui M, Zhang Y, Shang X. Prognostic value of the systemic inflammation response index in patients with acute ischemic stroke. Brain Behav. 2022;12(6):e2619. doi:10.1002/brb3.2619
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi:10.1002/cncr.30057
   PubMed Web of Science ®Google Scholar
• Cai X, Hu J, Wen W, et al. Association between the geriatric nutritional risk index and the risk of stroke in elderly patients with hypertension: a longitudinal and cohort study. Front Nutr. 2022;9:1048206. doi:10.3389/fnut.2022.1048206
   PubMed Web of Science ®Google Scholar
• Cai X, Hu J, Wang M, et al. Association between the sarcopenia index and the risk of stroke in elderly patients with hypertension: a cohort study. Aging. 2023;15(6):2005–2032. doi:10.18632/aging.204587
   PubMedGoogle Scholar
• Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28(1):112–118. doi:10.1093/bioinformatics/btr597
   PubMed Web of Science ®Google Scholar
• Zhang YX, Shen ZY, Jia YC, et al. The Association of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and systemic inflammation response index with short-term functional outcome in patients with acute ischemic stroke. J Inflamm Res. 2023;16:3619–3630. doi:10.2147/JIR.S418106
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xia J, He H, Liang S, Zhang H, Gan W. Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease. Front Endocrinol. 2022;13:981196. doi:10.3389/fendo.2022.981196
   PubMed Web of Science ®Google Scholar
• Bai YY, Xi Y, Yin BB, Zhang JH, Chen F, Zhu B. Reference intervals of systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio during normal pregnancy in China. Eur Rev Med Pharmacol Sci. 2023;27(3):1033–1044. doi:10.26355/eurrev_202302_31199
   PubMed Web of Science ®Google Scholar
• Kosidło JW, Wolszczak-Biedrzycka B, Matowicka-Karna J, Dymicka-Piekarska V, Dorf J. Clinical significance and diagnostic utility of NLR, LMR, PLR and SII in the course of COVID-19: a literature review. J Inflamm Res. 2023;16:539–562. doi:10.2147/JIR.S395331
   PubMed Web of Science ®Google Scholar
• Li P, Li H, Ding S, Zhou J. NLR, PLR, LMR and MWR as diagnostic and prognostic markers for laryngeal carcinoma. Am J Transl Res. 2022;14(5):3017–3027.
   PubMed Web of Science ®Google Scholar
• Misiewicz A, Dymicka-Piekarska V. Fashionable, but what is their real clinical usefulness? NLR, LMR, and PLR as a promising indicator in colorectal cancer prognosis: a systematic review. J Inflamm Res. 2023;16:69–81. doi:10.2147/JIR.S391932
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang K, Zheng H, Zhao X, Xie S, Liu C. Monocyte lymphocyte ratio predicts the new-onset of chronic kidney disease: a cohort study. Clin Chim Acta. 2020;503:181–189. doi:10.1016/j.cca.2019.11.021
   PubMed Web of Science ®Google Scholar
• Jin Z, Wu Q, Chen S, et al. The Associations of Two Novel Inflammation Indexes, SII and SIRI with the risks for cardiovascular diseases and all-cause mortality: a ten-year follow-up study in 85,154 individuals. J Inflamm Res. 2021;14:131–140. doi:10.2147/JIR.S283835
   PubMed Web of Science ®Google Scholar
• Chu M, Luo Y, Wang D, et al. Systemic inflammation response index predicts 3-month outcome in patients with mild acute ischemic stroke receiving intravenous thrombolysis. Front Neurol. 2023;14:1095668. doi:10.3389/fneur.2023.1095668
   PubMed Web of Science ®Google Scholar
• Wang P, Guo X, Zhou Y, et al. Monocyte-to-high-density lipoprotein ratio and systemic inflammation response index are associated with the risk of metabolic disorders and cardiovascular diseases in general rural population. Front Endocrinol. 2022;13:944991. doi:10.3389/fendo.2022.944991
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
   PubMed Web of Science ®Google Scholar
• Xiao S, Wang X, Zhang G, et al. Association of systemic immune inflammation index with estimated pulse wave velocity, atherogenic index of plasma, triglyceride-glucose index, and cardiovascular disease: a large cross-sectional study. Mediators Inflamm. 2023;2023:1966680. doi:10.1155/2023/1966680
   PubMed Web of Science ®Google Scholar
• Dang H, Mao W, Wang S, et al. Systemic inflammation response index as a prognostic predictor in patients with acute ischemic stroke: a propensity score matching analysis. Front Neurol. 2022;13:1049241. doi:10.3389/fneur.2022.1049241
   PubMed Web of Science ®Google Scholar
• Anrather J, Iadecola C. Inflammation and Stroke: an Overview. Neurotherapeutics. 2016;13(4):661–670. doi:10.1007/s13311-016-0483-x
   PubMed Web of Science ®Google Scholar
• Xia W, Han J, Huang G, Ying W. Inflammation in ischaemic brain injury: current advances and future perspectives. Clin Exp Pharmacol Physiol. 2010;37(2):253–258. doi:10.1111/j.1440-1681.2009.05279.x
   PubMed Web of Science ®Google Scholar
• Jin R, Liu L, Zhang S, Nanda A, Li G. Role of inflammation and its mediators in acute ischemic stroke. J Cardiovasc Transl Res. 2013;6(5):834–851. doi:10.1007/s12265-013-9508-6
   PubMed Web of Science ®Google Scholar
• McCabe JJ, Kelly PJ. Inflammation, cholesterol, and stroke risk: building evidence for a dual target strategy for secondary prevention. Stroke. 2021;52(9):2837–2838. doi:10.1161/STROKEAHA.121.035676
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a new target for prevention. Stroke. 2021;52(8):2697–2706. doi:10.1161/STROKEAHA.121.034388
   PubMed Web of Science ®Google Scholar
• Li J, Lin J, Pan Y, et al. Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study. J Neuroinflammation. 2022;19(1):131. doi:10.1186/s12974-022-02467-1
   PubMed Web of Science ®Google Scholar
• Coveney S, McCabe JJ, Murphy S, O’Donnell M, Kelly PJ. Anti-inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2020;5(5):CD012825. doi:10.1002/14651858.CD012825.pub2
   PubMedGoogle Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–762. doi:10.1056/NEJMoa1809798
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–410. doi:10.1016/j.jacc.2012.10.027
   PubMed Web of Science ®Google Scholar
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. doi:10.1056/NEJMoa1912388
   PubMed Web of Science ®Google Scholar
• Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142(20):1890–1900. doi:10.1161/CIRCULATIONAHA.120.050771
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet A, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847. doi:10.1056/NEJMoa2021372
   PubMed Web of Science ®Google Scholar
• Pusceddu I, Herrmann W, Kleber ME, et al. Subclinical inflammation, telomere shortening, homocysteine, vitamin B6, and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Eur J Nutr. 2020;59(4):1399–1411. doi:10.1007/s00394-019-01993-8
   PubMed Web of Science ®Google Scholar
• Schroecksnadel K, Grammer TB, Boehm BO, März W, Fuchs D. Total homocysteine in patients with angiographic coronary artery disease correlates with inflammation markers. Thromb Haemost. 2010;103(05):926–935. doi:10.1160/TH09-07-0422
   PubMedGoogle Scholar
• Fang P, Li X, Shan H, et al. Ly6C + inflammatory monocyte differentiation partially mediates hyperhomocysteinemia-induced vascular dysfunction in type 2 diabetic db/db mice. Arterioscler Thromb Vasc Biol. 2019;39(10):2097–2119. doi:10.1161/ATVBAHA.119.313138
   PubMed Web of Science ®Google Scholar
• Youssef MY, Mojiminiyi OA, Abdella NA. Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease. Transl Res. 2007;150(3):158–163. doi:10.1016/j.trsl.2007.02.006
   PubMed Web of Science ®Google Scholar
• McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circ Res. 2015;116(6):1022–1033. doi:10.1161/CIRCRESAHA.116.303697
   PubMed Web of Science ®Google Scholar
• Liu Q, Han L, Du Q, Zhang M, Zhou S, Shen X. The association between oxidative stress, activator protein-1, inflammatory, total antioxidant status and artery stiffness and the efficacy of olmesartan in elderly patients with mild-to-moderate essential hypertension. Clin Exp Hypertens. 2016;38(4):365–369. doi:10.3109/10641963.2015.1131285
   PubMed Web of Science ®Google Scholar
• Schiffrin EL. Immune mechanisms in hypertension and vascular injury. Clin Sci. 2014;126(4):267–274. doi:10.1042/CS20130407
   Web of Science ®Google Scholar
• Barrows IR, Ramezani A, Raj DS. Inflammation, immunity, and oxidative stress in hypertension-partners in crime. Adv Chronic Kidney Dis. 2019;26(2):122–130. doi:10.1053/j.ackd.2019.03.001
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A. Ischemic stroke pathogenesis: genetics, epigenetics and inflammation. Curr Pharm Des. 2020;26(34):4207–4208. doi:10.2174/138161282634200831110542
   PubMed Web of Science ®Google Scholar
• Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181–198. doi:10.1016/j.neuron.2010.07.002
   PubMed Web of Science ®Google Scholar
• Gauberti M, De Lizarrondo SM, Vivien D. The “inflammatory penumbra” in ischemic stroke: from clinical data to experimental evidence. Eur Stroke J. 2016;1(1):20–27. doi:10.1177/2396987316630249
   PubMedGoogle Scholar
• Jayaraj RL, Azimullah S, Beiram R, Jalal FY, Rosenberg GA. Neuroinflammation: friend and foe for ischemic stroke. J Neuroinflammation. 2019;16(1):142. doi:10.1186/s12974-019-1516-2
   PubMed Web of Science ®Google Scholar
• Iadecola C, Buckwalter MS, Anrather J. Immune responses to stroke: mechanisms, modulation, and therapeutic potential. J Clin Invest. 2020;130(6):2777–2788. doi:10.1172/JCI135530
   PubMed Web of Science ®Google Scholar
• Schäfer MK, Schwaeble WJ, Post C, et al. Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol. 2000;164(10):5446–5452. doi:10.4049/jimmunol.164.10.5446
   PubMed Web of Science ®Google Scholar
• Mocco J, Mack WJ, Ducruet AF, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res. 2006;99(2):209–217. doi:10.1161/01.RES.0000232544.90675.42
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Ninomiya I, Hatakeyama M, Takahashi T, Shimohata T. Microglia and monocytes/macrophages polarization reveal novel therapeutic mechanism against stroke. Int J Mol Sci. 2017;18(10):2135. doi:10.3390/ijms18102135
   PubMed Web of Science ®Google Scholar
• Alawieh A, Langley EF, Tomlinson S. Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice. Sci Transl Med. 2018;10(441):eaao6459. doi:10.1126/scitranslmed.aao6459
   PubMed Web of Science ®Google Scholar
• Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589–610. doi:10.1038/s41573-021-00198-1
   PubMed Web of Science ®Google Scholar
• Bäck M, Yurdagul A, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389–406. doi:10.1038/s41569-019-0169-2
   PubMed Web of Science ®Google Scholar